Peptide-based immunotherapy: a novel strategy for allergic disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Expert Review of Vaccines

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14760584.4.6.881PMID 16372883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of interleukin‐10 and suppressor of cytokine signalling‐3 gene expression following peptide immunotherapy

  2006cited by this paper
• T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory Activity

  2005cited by this paper
• Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects

  2005cited by this paper
• Peptide-based therapeutic vaccines for allergic and autoimmune diseases

  2005cited by this paper
• Transplantation tolerance induced by intranasal administration of HY peptides.

  2004cited by this paper
• Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis

  2004cited by this paper
• Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides.

  2004cited by this paper
• In Vivo Instruction of Suppressor Commitment in Naive T Cells

  2004cited by this paper
• Vaccination with genetically engineered allergens prevents progression of allergic disease

  2004cited by this paper
• Fatalities following allergen immunotherapy

  2004cited by this paper
• A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells

  2003cited by this paper
• Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial.

  2003cited by this paper
• Tolerogenic dendritic cells.

  2003cited by this paper
• Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial.

  2002cited by this paper
• β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

  2001cited by this paper
• Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells

  2001cited by this paper
• Allergen-Derived T Cell Peptide-Induced Late Asthmatic Reactions Precede the Induction of Antigen-Specific Hyporesponsiveness in Atopic Allergic Asthmatic Subjects1

  2001cited by this paper
• Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination

  2001cited by this paper
• Allergy and allergic diseases. First of two parts.

  2001cited by this paper
• Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.

  2001cited by this paper
• Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens.

  2001cited by this paper
• Allergen immunotherapy: does it work and, if so, how and for how long?

  2000cited by this paper
• Modulation of Th2 Responses by Peptide Analogues in a Murine Model of Allergic Asthma: Amelioration or Deterioration of the Disease Process Depends on the Th1 or Th2 Skewing Characteristics of the Therapeutic Peptide1

  2000cited by this paper
• Inducing Tolerance by Intranasal Administration of Long Peptides in Naive and Primed CBA/J Mice1

  2000cited by this paper
• Immunoglobulin E–independent Major Histocompatibility Complex–restricted T Cell Peptide Epitope–induced Late Asthmatic Reactions

  1999cited by this paper
• Immunotherapy in asthma: an updated systematic review

  1999cited by this paper
• Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10.

  1999cited by this paper
• Abundant empty class II MHC molecules on the surface of immature dendritic cells.

  1999cited by this paper
• The safety and efficacy of ALLERVAX CAT in cat allergic patients.

  1999cited by this paper
• IL‐10‐induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy

  1999cited by this paper
• Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis.

  1999cited by this paper
• Bystander suppression of murine collagen‐induced arthritis by long‐term nasal administration of a self type II collagen peptide

  1998cited by this paper
• Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

  1998cited by this paper
• Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease.

  1998cited by this paper
• Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats.

  1998cited by this paper
• Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.

  1998cited by this paper
• Effects of peptide therapy on ex vivo T-cell responses.

  1998cited by this paper
• Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis.

  1998cited by this paper
• Discontinuing venom immunotherapy: extended observations.

  1998cited by this paper
• Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology.

  1998cited by this paper
• Clinical efficacy of specific immunotherapy to cat dander: a double‐blind placebo‐controlled trial

  1997cited by this paper
• Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.

  1997cited by this paper
• Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1

  1997cited by this paper
• Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies.

  1997cited by this paper
• Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis.

  1997cited by this paper
• Immune Deviation‐the Third Dimension of Nondeletional T Cell Tolerance

  1996cited by this paper
• Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).

  1996cited by this paper
• A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells

  1996cited by this paper
• Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes

  1996cited by this paper
• Treatment of cat allergy with T-cell reactive peptides.

  1996cited by this paper
• Mucosal tolerance and suppression of collagen‐induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184‐198 of bovine type II collagen (CII) expressing a dominant T cell epitope

  1996cited by this paper
• Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects.

  1996cited by this paper
• T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis.

  1994cited by this paper
• Peripheral clonal deletion of antiviral memory CD8+ T cells

  1993cited by this paper
• Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I.

  1993cited by this paper
• Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice

  1993cited by this paper
• Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity.

  1993cited by this paper
• Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen

  1993cited by this paper
• Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

  1992cited by this paper
• Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.

  1992cited by this paper
• Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy.

  1992cited by this paper
• Functional inactivation of Dermatophagoides spp. (house dust mite) reactive human T‐cell clones

  1991cited by this paper
• Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs.

  1991cited by this paper
• MHC Class II and allergen‐specific T cell clones

  1991cited by this paper
• Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy.

  1991cited by this paper
• Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity.

  1990cited by this paper
• Antigen presentation by keratinocytes induces tolerance in human T cells

  1990cited by this paper
• Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein

  1989cited by this paper
• Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes.

  1988cited by this paper
• Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation

  1986cited by this paper
• Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin

  1983cited by this paper

• Peptide-Based Therapeutics in Autoimmune Diseases: Restoring Immune Balance Through Precision

  2026cites this paper
• Vaccines as therapies for food allergies.

  2021cites this paper
• Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection

  2020cites this paper
• Emerging Food Allergy Therapies

  2020cites this paper
• Pediatric Food Allergy: A Clinical Guide

  2020cites this paper
• Title Expression of recombinant T-cell epitopes of maj or Japanese cedar pollen allergens fused with ch olera toxin B subunit in bacterial strains

  2018cites this paper
• Tổng quan về liệu pháp miễn dịch đặc hiệu với dị nguyên

  2018cites this paper
• Peptide and Recombinant Allergen Vaccines for Food Allergy

  2018cites this paper
• Expression of recombinant T-cell epitopes of major Japanese cedar pollen allergens fused with cholera toxin B subunit in Escherichia coli.

  2015cites this paper
• Rice seed for delivery of vaccines to gut mucosal immune tissues.

  2015cites this paper
• Rice Seed-Based Allergy Vaccines: Induction of Allergen-Specific Oral Tolerance Against Cedar Pollen and House Dust Mite Allergies

  2014cites this paper
• Peptide based immunotherapy: a pivotal tool for allergy treatment.

  2014cites this paper
• Update on the use of transgenic rice seeds in oral immunotherapy.

  2013cites this paper
• Oral immunotherapy with transgenic rice seed containing destructed Japanese cedar pollen allergens, Cry j 1 and Cry j 2, against Japanese cedar pollinosis.

  2013cites this paper
• Towards a Pan-Anti-Allergy Vaccine

  2013cites this paper
• Immunotherapy in Allergic Skin Disease

  2012cites this paper
• T Cell Epitopes of the Timothy Grass Pollen Allergen Phl p 5 of Mice and Men and the Detection of Allergen-Specific T Cells Using Class II Ultimers

  2012cites this paper
• Cur l 3, a major allergen of Curvularia lunata-derived short synthetic peptides, shows promise for successful immunotherapy.

  2011cites this paper
• Oral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone mice

  2011cites this paper
• Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases.

  2011cites this paper
• The lymph as a pool of self-antigens.

  2011cites this paper
• Seed-based oral vaccines as allergen-specific immunotherapies

  2011cites this paper
• An Expanded Self-Antigen Peptidome Is Carried by the Human Lymph As Compared to the Plasma

  2010cites this paper
• Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3‐ and transforming growth factor‐β‐associated mechanisms

  2010cites this paper
• Role of high‐affinity HLA‐DP specific CLIP‐derived peptides in beryllium binding to the HLA‐DPGlu69 berylliosis‐associated molecules and presentation to beryllium‐sensitized T cells

  2009cites this paper
• Bypassing T cells using a B cell mimotope allergy vaccine

  2009cites this paper
• The Major Cat Allergen, Fel d 1, in Diagnosis and Therapy

  2009cites this paper
• Computer-aided biotechnology: from immuno-informatics to reverse vaccinology.

  2008cites this paper
• Mapping of human T-cell epitopes of allergens.

  2008cites this paper
• The Role of T Cell Recognition in the Immune Response Against Lipocalin

  2007cites this paper
• Characterizing the interaction between susceptibility genes to Berylliosis and beryllium: determining the antigen beryllium and molecular mechanisms to prevent the BE/HLA binding as a immuno-modulatory therapy against Berylliosis

  2007cites this paper
• Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches

  2007cites this paper
• The Role of T Cell Recognition in the Immune Response Against Lipocalin Allergens

  2007cites this paper
• A double-blind randomized placebo-controlled trial with short-term beta-glucuronidase therapy in children with chronic rhinoconjunctivitis and/or asthma due to dust mite allergy.

  2006cites this paper
• CHARACTERIZING THE INTERACTION BETWEEN SUSCEPTIBILITY GENES TO BERYLLIOSIS AND BERYLLIUM. DETERMINING THE ANTIGEN BERYLLIUM AND MOLECULAR MECHANISMS TO PREVENT THE BE/HLA BINDING AS A IMMUNO-MODULATORY THERAPY AGAINST BERYLLIOSIS.

  2006cites this paper
• Prospects for peptide-based immunotherapy for dog allergy

  2006cites this paper
• Allergen immunotherapy: immunomodulatory treatment for allergic diseases

  2006cites this paper
• Novel vaccines and adjuvants for allergen-specific immunotherapy.

  2006cites this paper